Plavix gets extension on U.S. market exclusivity

BOSTON (MarketWatch) — In a move that had been widely expected, Bristol-Myers Squibb (NYSE:BMY) and partner Sanofi-Aventis (NYSE:SNY) announced that they have been given a six-month extension on U.S. market exclusivity for their blockbuster blood-thinner Plavix. U.S. regulators granted the extension after the companies agreed to run certain pediatric studies with the drug. Plavix, one of the world’s best-selling medications, is now expected to lose U.S. patent protection in May 2012, which will open up the door to cheaper generic competition.

This entry was posted in Manufacturers Updates, Uncategorized. Bookmark the permalink.

Comments are closed.